Trial Profile
Randomized Phase II Trial of Docetaxel (Taxotere) and Oblimersen (Antisense Oligonucleotide Directed to BCL-2) Versus Taxotere Alone in Patients With Hormone-Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Oblimersen (Primary) ; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 07 Sep 2009 Status changed from active, no longer recruiting to completed.
- 01 Jul 2009 Primary endpoint 'Prostate specific antigen response' has not been met.
- 01 Jul 2009 Status change from active, no longer recruiting to completed